Search for: "Zimmer Production, Inc. " Results 141 - 160 of 168
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Feb 2010, 7:28 am by Beck, et al.
Zimmer, Inc., 2004 WL 5254312, at *1 (D. [read post]
1 Oct 2009, 2:14 am
Organon USA, Inc., 2007 WL 4365312 (D.N.J. [read post]
23 Jun 2009, 12:00 pm
Southern District of Indiana MDL No. 2055, In re Zimmer Holdings, Inc., Securities, Derivative and Employee Retirement Income Security Act (ERISA) Litig. [read post]
10 Jun 2009, 8:28 am
Zimmer did not issue a recall on the product, but did stop selling the products in July, 2008. [read post]
6 Feb 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: WTO report confirms USTR lost on key issue of whether China’s thresholds for criminal IP enforcement are too high (Managing Intellectual Property) (IP Justice) (IP Justice) (China Hearsay) (China Law Blog) US: Judd Gregg to be nominated as Secretary of Commerce (Inventive Step) (IP Watchdog) (Peter Zura's 271 Patent Blog)… [read post]
7 Sep 2008, 2:47 pm
The outcome as a result of the September 2007 settlement was that hip and knee device manufacturers Zimmer, Inc., DePuy Orthopaedics, Inc. [read post]
23 Aug 2008, 11:22 am
Department of Justice settlement with four medical device companies, Zimmer, Inc., DePuy Orthopaedics, Inc., Biomet, Inc., and Smith & Nephew, Inc., these back door consulting agreements must now be made public. [read post]
21 Aug 2008, 11:00 am
Zimmer Holdings, Inc., 2008 WL 3153442, at *5-6 (N.D. [read post]
14 Aug 2008, 11:00 am
Zimmer Holdings, Inc., 2008 WL 3153442, at *5-6 (N.D. [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]